Development of a Nano-Formulated Drug Delivery System for Enhanced Bioavailability of Hydrophobic Anticancer Agents

Project Abstract

Hydrophobic anticancer agents often face significant challenges in clinical application due to poor aqueous solubility, limited bioavailability, and non-specific toxicity, which collectively compromise their therapeutic efficacy. This study aims to develop a nano-formulated drug delivery system designed to enhance the bioavailability of hydrophobic anticancer drugs, thereby improving their therapeutic index and reducing adverse effects. The research adopts a comprehensive approach involving the synthesis, characterization, and evaluation of nanoparticle-based carriers such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles, optimized for encapsulating hydrophobic anticancer agents like Paclitaxel and Curcumin. The synthesis process involves solvent evaporation, emulsification, and high-pressure homogenization techniques, followed by surface modification with targeting ligands to facilitate tumor-specific delivery. Characterization of these nano-formulations encompasses particle size analysis, zeta potential measurement, drug encapsulation efficiency, and in vitro stability studies using dynamic light scattering (DLS), transmission electron microscopy (TEM), and Fourier-transform infrared spectroscopy (FTIR). Further, the release kinetics of the encapsulated drugs are assessed under simulated physiological conditions to determine sustained-release profiles. In vitro studies utilize cancer cell lines such as MCF-7 and A549 to evaluate cytotoxicity, cellular uptake, and apoptosis induction, comparing nano-formulated drugs with free drugs. Pharmacokinetic and biodistribution analyses in animal models, specifically murine xenograft models, are conducted to assess the bioavailability, tissue distribution, and tumor targeting efficiency of the nano-delivery systems. Additionally, the study investigates potential immunogenicity and toxicity profiles associated with the formulations using standard biochemical and histopathological assays. The results demonstrate that the nano-formulated systems significantly improve aqueous solubility, enhance cellular uptake, and extend circulation time, leading to increased accumulation within tumor tissues and improved anticancer efficacy compared to conventional formulations. Moreover, targeted surface modifications further enhance specificity, reducing off-target effects and systemic toxicity. The study explores the relationship between nanoparticle characteristics and biological performance, providing insights into optimizing design parameters for clinical translation. Ultimately, this research presents a promising nanotechnological platform for delivering hydrophobic anticancer agents, with the potential to revolutionize chemotherapy protocols by maximizing therapeutic benefits while minimizing side effects. The findings contribute valuable knowledge toward the development of personalized, targeted cancer treatments, fostering advancements in nanomedicine and pharmaceutical sciences.

Project Overview

What This Project Is About

---

This project explores ways to improve how certain cancer drugs are delivered in the body. Some anticancer drugs are hydrophobic, meaning they do not dissolve well in water, which makes it hard for the body to absorb them effectively. The project focuses on creating tiny particles, called nanocarriers, that can carry these drugs more efficiently. The goal is to design a system where the drug is packaged in nanoparticles that can better reach the cancer cells, improving the drug's effectiveness and reducing side effects.

---

---

The Problem It Addresses

---

Many popular anticancer drugs do not dissolve properly in the body’s fluids, leading to low absorption and effectiveness. This limits their ability to kill cancer cells and often requires higher doses, which causes more side effects. Existing delivery methods may not always ensure the drug reaches the target site, decreasing the treatment's success. This project aims to solve these issues by developing a delivery system that makes hydrophobic drugs more bioavailable, meaning the body can absorb and use them better, ultimately improving patient outcomes.

---

---

Objectives of the Project

---

1. Design and prepare nano-sized carriers for hydrophobic anticancer drugs.
2. Improve the solubility and stability of the drug within these carriers.
3. Evaluate how well the nanoformulation improves drug absorption in biological models.
4. Analyze the release profile of the drug from the nano-carriers over time.
5. Assess the safety and toxicity of the nanoformulated system.

---

---

What You Will Do Step by Step

---

1. Research existing methods for creating nanocarriers for drugs.
2. Design and prepare nano-sized carriers loaded with the anticancer drug.
3. Conduct tests to measure how well the drug dissolves and remains stable inside the nano-carrier.
4. Use laboratory models, like cell cultures, to test how effectively the drug is absorbed when delivered via nanocarriers.
5. Measure the rate and extent of drug release from the nanocarriers over a period.
6. Test the safety of the nanocarrier system in biological settings to identify any toxicity.
7. Analyze collected data to determine if the nanoformulation improves drug delivery.
8. Draw conclusions and suggest ways to optimize the delivery system for future use.

---

---

Expected Outcome

The project aims to develop a nano-sized delivery system that significantly enhances the bioavailability of hydrophobic anticancer drugs. This improved system is expected to enable the drug to reach cancer cells more effectively, reducing the required dosage and minimizing side effects. Ultimately, the research could lead to more efficient cancer treatments, better patient outcomes, and pave the way for new drug delivery strategies in medicine.